Memorandum of Understanding between Beijing Pharma and Biotech Center, Beijing, P.R. China and BioDeakin, Australia
Whereas, Beijing Pharma and Biotech Center (herein after referred to “BPBC”) is the principal health research agency of the Beijing local government; it is a component of Beijing Municipal of Science and Technology Commission (BMSTC). Established in 1996 and initially function as the development and implementation of Beijing Government Grants Policy, BPBC serves as the focal point for advisory industrial policy, mandatory project management for government and international bridge between Chinese Biotech & Pharmaceutical Industry and rest of the world. It keeps close relationship with government, well known research institutes, universities, biotechnology and pharmaceutical enterprises, academic groups and other organizations related. It depends on the innovation advantages in Beijing and promotes the extensive exchanges between China and abroad.
Whereas, BioDeakin is a whole-of-university initiative, created to advance scholarship, research and teaching across a range of applied biotechnology areas. This multi-disciplinary grouping of scientists encompasses the University's strengths in biosciences. The goal is to generate and transform knowledge from biotechnology into practical solutions, which will advance health, social, environmental and economic development. BioDeakin has been instrumental in the formation of BioGeelong, with Prof Andrew Parratt as the inaugural Chairman, a role he held for 3 years. Its membership includes all major organisations with interests in biotechnology related research in the Geelong region (Deakin University, ChemGenex, Barwon Health, CSIRO Australian Animal Health Laboratories, CSIRO Textiles and Fibre Technology, Primary Industries Victoria Marine and Freshwater Research Institute, The City of Greater Geelong, The Gordon Institute of TAFE, PathCare and Coulter Roache).
Now therefore BioDeakin and BPBC enter into a Memorandum of Understanding to establish a program of exchange and collaboration in areas of benefit to both institutions.
The purpose of the cooperation between BioDeakin and BPBC is as follows:
To promote interest in development and transfer of bio-pharmaceutical, and medical technology of the member institutions and thereby to attract capital investments between Victoria and Beijing, P.R. China.
To achieve these goals, BioDeakin and BPBC will, insofar as the means of each allow:
- Promote attendance at conferences and other meetings organized be each organization
- BPBC shall endeavor to arrange a delegation of company representatives to attend BioDeakin’s key conference;
- BioDeakin shall endeavor to arrange representatives to attend BPBC’s Beijing International Healthcare Industry Forum scheduled for October, 2012 and subsequent years;
- Promote information through a quarterly letter in each other’s newsletters and updates relative to academic research.
- Information sharing can include logo’s and links on each other’s web sites, listing of events on community event calendars, letters from representatives of each organization included in newsletters and other avenues for communication.
- Most of the information will be focus on each other’s focus areas, including Bioinformatics, Biomaterials, Comparative Genetics, Nanomedicine-Immunology and Molecular Biomedical Research, Industrial Biotechnology and the Bioeconomy, Metabolic Research;
- Arrange networking between BioDeakin groups and life science institutes and companies associated with BPBC
- BPBC shall provide information on growing an international business with a focus on China;
- BioDeakin shall provide information on growing an international business with a focus on Australia;
- BioDeakin shall endeavor to provide assistance to visiting companies/delegations including but not limited to facilitating meetings;
- BPBC shall endeavor to provide assistance to visiting companies/delegations including but not limited to facilitating meetings;
- Encourage and support companies and institutes from both parties to exchange personnel for further understanding, as a promotion for a closer collaboration between Beijing and Victoria;
- Arrange working groups and other such activities as the parties may time to time agree upon.
To the extent provided by law, any technical or commercial trade secret information, the technical specifications, related materials, document and other such information provided by one party hereto to other party shall be deemed to be confidential and proprietary (“Confidential Information”). As a condition of the mutual exchange and disclosure of the Confidential Information, each receiving party agrees, during the term of this MOU and one year thereafter, not to disclose, use, copy or reproduce the Confidential Information except to the extent reasonably necessary for the purpose of this MOU.
This general Memorandum of Understanding shall be identified as the parent document of any program agreement executed between the parties. No modification, alteration or amendment of this MOU shall be effective unless in writing and signed by the Parties.
Further agreements concerning any program shall provide details concerning the specific commitments made by each party and shall note become effective until they have been reduced to writing and executed by the duly authorized representatives of the parties. The scope of the activities under this agreement shall be determined by the funds regularly available at both institutions for the types of collaboration undertaken and by financial assistances as may be obtained by either institution from external sources.
The Parties understand that they are proceeding at their own risk and they understand that costs regarding the subject matter under this MOU are to be paid for by the Party who incurs the cost. Nothing contained in this the MOU is to be construed as providing for the sharing of profits or losses arising out of the efforts of either or both parties. Neither Party will be liable to the other for any costs, expenses, risks or liabilities arising out of the other Parties efforts in connection with this MOU.
This MOU is effective from the date set forth below, unless terminated at any time by either party for any reason, on written notice to the other party.
This MOU shall be deemed to have been made in China and shall be interpreted and enforced in accordance with the laws of People Republic China. Executed by BIOSA and BPBC in duplicate copies, each of them shall be deemed as original. This MOU has been concluded and executed in both English and Chinese language versions. Both language versions shall have equal force and effect and shall be consulted if a question of interpretation arises in relation to this MOU.
Beijing Pharma and Biotech Center
Printed name: ___________________
Printed name: __________________